A5011364521- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Occupational and environmental lung diseases
- Glioma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Peptidase Inhibition and Analysis
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Pleural and Pulmonary Diseases
- Cancer therapeutics and mechanisms
- RNA modifications and cancer
- Neuroendocrine Tumor Research Advances
- Myasthenia Gravis and Thymoma
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Cancer Diagnosis and Treatment
- Pituitary Gland Disorders and Treatments
- Radiation Dose and Imaging
- Pericarditis and Cardiac Tamponade
- Multiple and Secondary Primary Cancers
- Quinazolinone synthesis and applications
- Diabetes Management and Research
Ca' Foncello Hospital
2019-2024
Sapienza University of Rome
2023
AULSS 2 Marca Trevigiana
2011-2019
Institut Gustave Roussy
2013-2017
University of Padua
2012-2017
Istituto Oncologico Veneto
2011-2017
Istituti di Ricovero e Cura a Carattere Scientifico
2011-2017
Veneto Institute of Molecular Medicine
2012-2016
Ospedale di Rivoli
1998
Osimertinib has confirmed effectiveness in this real-world population of patients with EGFR-mutant advanced non-small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients at least three metastatic sites, brain metastases, and symptoms diagnosis seem to have worse prognosis.Osimertinib became the standard treatment for untreated cancer (aNSCLC) following results reported phase...
The observational multicenter prospective FLOWER study (NCT04965701) confirmed effectiveness and safety of osimertinib in the real-world (RW) management untreated EGFR-mutant advanced non-small cell lung cancer (aNSCLC) patients.
Tyrosine-kinase inhibitors (TKIs) represent the best treatment for advanced non-small cell lung cancer (NSCLC) with common exon 19 deletion or 21 epidermal growth factor receptor mutation (EGFRm). This is an observational study investigating epidemiology, clinical features and outcome of NSCLC cases harbouring rare/complex EGFRm.Among 764 non-squamous known EGFRm status, 26(3.4%) harboured EGFRm. Patients receiving first-line TKIs (N = 17) achieved median Progression Free Survival (PFS)...
Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M-) patients. We have also described progression patterns treatment sequences. Patients & methods: is a retrospective multicenter Italian observational including consecutive Caucasian referred between 2014 2018. Results: 167...
Liquid biopsy is currently approved for management of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients. However, one unanswered question whether the rate cell-free DNA (cfDNA)-negative samples due to technical limitations rather than tumor genetic characteristics. Using four microsatellite markers that map specific chromosomal loci often lost in cancer, we conducted a pilot study investigate other alterations, such as loss heterozygosity (LOH),...
circulating tumor DNA (ctDNA) is a source of genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim the study was to describe LB detection North Eastern Italy.we conducted multi-regional survey on ctDNA practices lung cancer patients.Median time from blood collection plasma separation 50 min (20-120 min), median extraction analysis 24 h (30 min-5 days) and turnaround (6 h-5 days). Four hundred seventy five patients 654...
Objectives: If concurrent chemoradiotherapy cannot be performed, induction chemotherapy followed by radical-intent surgical treatment is an acceptable option for non primarily resectable non-small-cell lung cancers (NSCLCs). No markers are available to predict which patients may benefit from local after induction. This exploratory study aims assess the feasibility and activity of multimodality treatment, including triple-agent radical surgery and/or radiotherapy in locally advanced NSCLCs....